Related Experiment Videos
[Perspectives for treatment of pulmonary fibrosis]
1Kliniki Chorób Płuc, Gruźlicy AM w Gdańsku.
Abstract:
Conventional therapy of fibrogenic lung diseases, based mainly on the use of glucocorticoids or immunosuppressive, cytotoxic agents, does not usually protect before progression of disease and accumulation of the excess connective tissue in lungs. This article is a review of potential new therapies in the treatment of pulmonary fibrosis. Novel therapies emerged from the use of animal models of pulmonary fibrosis and recent advances in the cellular and molecular biology of inflammatory reaction involve the use of substances directed against the action of pathogenic agents: growth factors, cytokines or oxidants. Thus, future therapeutic strategies will be aimed at more selective and effective methods of controlling the key elements of pulmonary fibrosis.
Insights
New treatments for pulmonary fibrosis focus on targeting specific disease mechanisms, moving beyond traditional therapies that often fail to halt lung scarring. Future strategies aim for more precise control over factors driving fibrotic lung disease progression.
Area of Science:
- Pulmonary Medicine
- Cellular Biology
- Molecular Biology
Context:
- Fibrogenic lung diseases, including pulmonary fibrosis, are characterized by progressive connective tissue accumulation.
- Current treatments like glucocorticoids and cytotoxic agents often fail to prevent disease progression.
- Understanding the cellular and molecular basis of lung inflammation is crucial for developing new therapies.
Purpose:
- To review emerging therapeutic strategies for pulmonary fibrosis.
- To explore novel treatments based on recent advances in understanding lung fibrosis.
- To identify future directions in controlling key fibrotic processes.
Summary:
- Review of novel therapies for pulmonary fibrosis, moving beyond conventional treatments.
- Emerging strategies target pathogenic factors like growth factors, cytokines, and oxidants.
- Future treatments will focus on selective and effective control of fibrotic mechanisms.
Impact:
- Potential for improved treatment outcomes in pulmonary fibrosis.
- Development of more targeted and effective therapies for lung scarring.
- Advancement of personalized medicine approaches for fibrotic lung diseases.